![Rachel Humphrey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rachel Humphrey
Directeur/Membre du Conseil chez
PYXIS ONCOLOGY, INC.
Fortune : 146 356 $ au 31/05/2026
Profil
Rachel W.
Humphrey is President & Chief Executive Officer at Normunity, Inc. since 2021.
She is an Independent Director at Pyxis Oncology, Inc. since 2022.
She serves as Director at Asylia Therapeutics, Inc. and as Director at Sporos Bioventures LLC since 2022.
Former roles include Director at CytomX Therapeutics Holdings LLC; Independent Director at Xilio Therapeutics, Inc. from 2019 to 2022; Director & Chief Medical Officer at Treadwell Therapeutics, Inc. in 2020; Vice President-Product Development at Bristol Myers Squibb Co. from 2003 to 2012; Head-Immuno Oncology at Eli Lilly & Co. in 2015; Chief Medical Officer & Executive Vice President at Mirati Therapeutics, Inc. from 2012 to 2013; Senior Vice President & Head-Immuno Oncology at AstraZeneca LP from 2013 to 2014; Chief Medical Officer & Senior Vice President at CytomX Therapeutics, Inc. from 2015 to 2019; Chief Medical Officer at Black Diamond Therapeutics, Inc. from 2020 to 2021; Head-Research & Development at Tio Bioventures in 2020; and Scientific Advisor at eFFECTOR Therapeutics, Inc. Education includes undergraduate studies at Harvard University and a doctorate from Case Western Reserve University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC. 0,13% | 20/04/2026 | 81 309 ( 0,13% ) | 146 356 $ | 31/05/2026 |
Postes actifs de Rachel Humphrey
| Sociétés | Poste | Début |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Directeur/Membre du Conseil | 11/08/2022 |
Normunity, Inc.
 Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Develops immuno-oncology medicines | Directeur Général | 01/10/2021 |
Sporos Bioventures, Inc.
 Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Provides healthcare services | Directeur/Membre du Conseil | 04/01/2022 |
Asylia Therapeutics, Inc.
 Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for the immune diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Rachel Humphrey
| Sociétés | Poste | Fin |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 03/02/2022 |
| BLACK DIAMOND THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 04/08/2021 |
Tio Bioventures
 Tio Bioventures Investment ManagersFinance Tio Bioventures invests in companies located in the United States. The firm focuses on companies operating in the field of biotechnology. It participates in early stage capital transactions. | Directeur Technique/Scientifique/R&D | 01/05/2020 |
Treadwell Therapeutics, Inc.
 Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a science driven clinical-stage multi-modality oncology company which develops medicines | Directeur Technique/Scientifique/R&D | 01/05/2020 |
| CYTOMX THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 19/08/2019 |
Formation de Rachel Humphrey
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
68
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cancer therapies | Health Technology |
Case Western Reserve University
 Case Western Reserve University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics Holdings LLC
 CytomX Therapeutics Holdings LLC Pharmaceuticals: MajorHealth Technology Engaged in the development of new generation targeted antibody therapeutics | Health Technology |
AstraZeneca LP
 AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The company is based in Wilmington, DE. | Health Technology |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Black Diamond Therapeutics, Inc.
 Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Pyxis Oncology, Inc.
 Pyxis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a preclinical oncology company focused on developing an arsenal of next-generation therapeutics | Health Technology |
Treadwell Therapeutics, Inc.
Treadwell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a science driven clinical-stage multi-modality oncology company which develops medicines | Health Technology |
Tio Bioventures
Tio Bioventures Investment ManagersFinance Tio Bioventures invests in companies located in the United States. The firm focuses on companies operating in the field of biotechnology. It participates in early stage capital transactions. | Finance |
Asylia Therapeutics, Inc.
Asylia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for the immune diseases | Health Technology |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
eFFECTOR Therapeutics, Inc.
 eFFECTOR Therapeutics, Inc. BiotechnologyHealth Technology Operates as a oncology company which develops therapies for cancer | Health Technology |
Normunity, Inc.
Normunity, Inc. Miscellaneous Commercial ServicesCommercial Services Develops immuno-oncology medicines | Commercial Services |
